Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Time to reach maximum observed steady state plasma concentration (Tss,max) of BGB-16673

Time frame: Phase 1a and Phase 2: Week 5 Day 1 pre-dose and up to 8 hours post-dose; Phase 1b: Week 5 Day 1 pre-dose and up to 6 hours post-dose

Minimum observed steady state plasma concentration (Css,min) of BGB-16673

Time frame: Phase 1a and Phase 2: Week 5 Day 1 pre-dose and up to 8 hours post-dose; Phase 1b: Week 5 Day 1 pre-dose and up to 6 hours post-dose

Steady state area under the plasma concentration-time curve (AUC) of BGB-16673

Time frame: Phase 1a and Phase 2: Week 5 Day 1 pre-dose and up to 8 hours post-dose; Phase 1b: Week 5 Day 1 pre-dose and up to 6 hours post-dose

Accumulation ratios of Cmax and AUC of BGB-16673

Time frame: Phase 1a: Day 1 pre-dose up to 72 hours post-dose, Week 5 pre-dose up to 8 hours post-dose; Phase 1b: Week 1 and Week 5 pre-dose up to 6 hours post-dose; Phase 2: Week 1 and Week 5 pre-dose up to 8 hours post-dose

Bruton's tyrosine kinase (BTK) protein degradation in peripheral blood after BGB-16673 monotherapy

Time frame: Phase 1a: Day 1 pre-dose up to 72 hours post-dose, Week 5 pre-dose and 8 hours post-dose, Week 9 pre-dose; Phase 1b: Week 1 and Week 5 pre-dose and 6 hours post-dose, Week 9 pre-dose; Phase 2: Week 1, Week 5, Week 9 pre-dose

Phase 1: Overall Response Rate (ORR)

ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator using International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Owen, and Lugano criteria.

Time frame: Up to approximately 3 years

Phase 1: Major Response Rate (MRR) in participants with Waldenstrom macroglobulinemia (WM)

MRR is defined as the percentage of participants who achieved complete response (CR), very good partial response (VGPR), and partial response (PR), as assessed by investigators for participants with WM only.

Time frame: Up to approximately 3 years

Phase 2: Number of participants with AEs and SAEs

Number of participants with AEs and SAEs as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE 5.0).

Time frame: From first dose of the study drug(s) to 30 days after the last dose or before initiation of a new anticancer therapy, whichever occurs first (up to approximately 3 years)

Phase 2: ORR in participants with R/R MCL as assessed by investigators

ORR is defined as the percentage of participants with partial response or better according to investigators and as determined by Lugano criteria.

Time frame: Up to approximately 3 years

Phase 2: Duration of Response (DOR)

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first as determined by IRC and by investigators.

Time frame: Up to approximately 3 years

Phase 2: Time to Response (TTR)

TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) as determined by IRC and by investigators.

Time frame: Up to approximately 3 years

Phase 2: Progression Free Survival (PFS)

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as determined by IRC and by investigators.

Time frame: Up to approximately 3 years

Phase 2: Overall Survival (OS)

OS is defined as the time from first study drug administration to the date of death due to any cause.

Time frame: Up to approximately 3 years

Phase 2: Best Overall Response (BOR) of Partial Response with Lymphocytosis (PR-L) in Participants with R/R CLL/SLL

BOR of PR-L or better as determined by IRC and by investigators per iwCLL criteria for CLL and per Lugano criteria for SLL

Time frame: Up to approximately 3 years

Phase 2: Change from baseline in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index-18 (NFLymSI-18) Disease-related Symptom Physical and Treatment Side Effect Subscales in participants with R/R MCL

The NFLymSI-18 questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score. A mixed model for repeated measures (MMRM) will be used to estimate the mean change from baseline for NFlymSI-18 subscales of Disease-Related Symptoms Physical (DRSP), and "treatment side effects" (TSE).

Time frame: Baseline and Day 1 of weeks 5, 13, 25, and 37

Phase 2: ORR assessed by the Investigator in participants with R/R CLL/SLL

ORR is defined as the percentage of participants with partial response or better as determined by investigators per iwCLL criteria for CLL and Lugano criteria for SLL.

Time frame: Up to approximately 3 years

Phase 2: Mean change from baseline for the Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu ) questionnaire Physical Well-being and Functional Well-being Subscales for participants with R/R CLL/SLL

FACT-Leu is a 44-item patient reported outcome questionnaire with five subscales used to measure health-related quality of life (HRQoL) in leukemia patients. Each question is scored from 0 (not at all) to 4 (very much).

Time frame: Baseline and Day 1 of weeks 5, 13, 25, and 37